Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

This study has been terminated.
(Portfolio consolidation.)
Sponsor:
Information provided by (Responsible Party):
Emergent BioSolutions
ClinicalTrials.gov Identifier:
NCT00893516
First received: May 5, 2009
Last updated: February 25, 2013
Last verified: February 2013
  Purpose

Evaluation of CD4 in combination with CHO chemotherapy in subjects with nodal involvement of non cutaneous Tcell lymphoma.


Condition Intervention Phase
T-cell Lymphoma
Biological: CHOP + CD4
Drug: CHOP
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.

Resource links provided by NLM:


Further study details as provided by Emergent BioSolutions:

Enrollment: 5
Study Start Date: May 2007
Study Completion Date: December 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
CHOP chemo therapy + CD4 therapy
Biological: CHOP + CD4
Active Comparator: 2
CHOP chemotherapy
Drug: CHOP

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • study is closed to enrollment

Exclusion Criteria:

  • study is closed to enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Emergent BioSolutions
ClinicalTrials.gov Identifier: NCT00893516     History of Changes
Other Study ID Numbers: GEN112
Study First Received: May 5, 2009
Last Updated: February 25, 2013
Health Authority: Netherlands: Medicines Evaluation Board (MEB)
Switzerland: Swissmedic
Germany: Federal Institute for Drugs and Medical Devices
Italy: Ministry of Health

Keywords provided by Emergent BioSolutions:
non cutaneous peripheral t-cell lymphoma with nodal involvement

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on November 25, 2014